Magnesium incorporation into β-TCP reduced its in vivo resorption by decreasing parathormone production

Journal of Biomedical Materials Research - Part A

Volumn 101 A, Issue 7, 2013, Pages 1986-1993

  Yassuda, Debora H ^a   Costa, Neusa F M ^a   Fernandes, Gustavo O ^b   Alves, Gutemberg G ^b   Granjeiro, José M ^b,c   Soares, Glória De A ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^c INSTITUTO NACIONAL DE METROLOGIA   (Brazil)

Author keywords

TCMP; Beta tricalcium phosphate; osteoprotegerin; parathormone; receptor activator of NF kB ligand

Indexed keywords

BETA TRICALCIUM PHOSPHATE; BIORESORBABLE MATERIALS; HISTOMORPHOMETRIC ANALYSIS; MULTIPLEXING TECHNOLOGIES; OSTEOCLASTOGENESIS; OSTEOPROTEGERIN; PARATHORMONE; RECEPTOR ACTIVATOR;

BIOCOMPATIBILITY; BONE; GRAFTING (CHEMICAL); GRANULATION; LIGANDS; METAL IONS;

TRANSMISSION CONTROL PROTOCOL;

CALCIUM PHOSPHATE; MAGNESIUM; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; OSTEOPROTEGERIN; PARATHYROID HORMONE;

ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; BONE REMODELING; CONTROLLED STUDY; IN VIVO STUDY; MACROPHAGE; MORPHOMETRICS; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PARATHYROID HORMONE RELEASE; PROTEIN EXPRESSION;

ANIMALS; BIOCOMPATIBLE MATERIALS; CALCIUM PHOSPHATES; CRYSTALLIZATION; IMMUNOASSAY; MAGNESIUM; MATERIALS TESTING; OSTEOCALCIN; OSTEOGENESIS; OSTEOPONTIN; OSTEOPROTEGERIN; PARATHYROID HORMONE; POWDERS; RANK LIGAND; RATS; RATS, WISTAR; TOOTH SOCKET; X-RAY DIFFRACTION;

EID: 84878326463     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.34502     Document Type: Article

References (32)

1. Rojbani H, Nyan M, Ohya K, Kasugai S,. Evaluation of the osteoconductivity of α-tricalcium phosphate, β-tricalcium phosphate, and hydroxyapatite combined with or without simvastatin in rat calvarial defect. J Biomed Mater Res A 2011; 98: 488-498.
2. Marchi J, Dantas ACS, Greil P, Bressiani JC, Bressiani AH, Müller FA,. Influence of Mg-substitution on the physicochemical properties of calcium phosphate powders. Mater Res Bull 2007; 42: 1040-1050.
3. Fawcet WJ, Hexby EJ, Male DA,. Magnesium physiology and pharmacology. Br J Anaesth 1999; 83: 302-320.
4. Landi E, Logroscino G, Proietti L, Tampieri A, Sandri M, Sprio S,. Biomimetic Mg-substituted hydroxyapatite: From synthesis to in vivo behaviour. J Mater Sci: Mater Med 2008; 19: 239-247.
5. Sader MS, Legeros RZ, Soares GA,. Human osteoblasts adhesion and proliferation on magnesium-substituted tricalcium phosphate dense tablets. J Mater Sci: Mater Med 2009; 20: 521-527.
6. Roy M, Bose S,. Osteoclastogenesis and osteoclastic resorption of tricalcium phosphate: Effect of strontium and magnesium doping. J Biomed Mater Res A 2012; 100: 2450-2461.
7. Yang W, Zhang Y, Yang J, Tan L, Yang K,. Potential antiosteoporosis effect of biodegradable magnesium implanted in STZ-induced diabetic rats. J Biomed Mater Res A 2011; 99: 386-394.
8. Yassuda-Mattos DH, Costa NMF, Tavares D, Fernandes GVO, Alves AT, Granjeiro JM, Soares GDA,. Study of bone repair in rat dental socket after implantation of porous granules of Beta-tricalcium phosphate (β-TCP) and Magnesium-substituted Beta-tricalcium phosphate (β-TCMP). Key Eng Mater 2012; 493-494: 263-268.
9. Liu F, Kohlmeier S, Wang CY,. Wnt signaling and skeletal development. Cell Signal 2008; 20: 99-1009.
10. Menezes R, Garlet TP, Trombone AP, Repeke CE, Letra A, Granjeiro JM, Campanelli AP, Garlet GP,. The potential role of suppressors of cytokine signaling in the attenuation of inflammatory reaction and alveolar bone loss associated with apical periodontitis. J Endod 2008; 34: 1480-1484.
11. Menezes R, Garlet TP, Letra A, Bramante CM, Campanelli AP, Figueira RC, Sogayar MC, Granjeiro JM, Garlet GP,. Differential patterns of receptor activator of nuclear factor kappa B ligand/osteoprotegerin expression in human periapical granulomas: Possible association with progressive or stable nature of the lesions. J Endod 2008; 34: 932-938.
12. Eriksen EF,. Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord 2010; 11: 219-227.
13. Paulo AO, Castro-Silva II, Oliveira DF, Machado ME, Bonetti-Filho I, Granjeiro JM,. Repair of critical-size defects with autogenous periosteum-derived cells combined with bovine anorganic apatite/collagen: An experimental study in rat calvaria. Braz Dent J 2011; 22: 322-328.
14. Dorozhkin SV,. Calcium orthophosphates as bioceramics: State of the art. J Funct Biomater 2010; 1: 22-107.
15. Kamitakahara M, Ohtsuki C, Miyazaki T,. Review paper: Behaviour of ceramic biomaterials from tricalcium phosphate in physiological condition. J Biomater Appl 2008; 23: 197-212.
16. Beuvelot J, Pascaretti-Grizon F, Filmon R, Moreu MF, Baslé MF, Chappard D,. In vitro assessment of osteoblast and macrophage mobility in presence of β-TCP particles by videomicroscopy. J Biomed Mater Res A 2011; 96: 108-115.
17. Ferron M, Wei J, Yoshizawa T, Delafatore A, Depinho RA, Teti A, Ducy P, Karsenty G,. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 2010; 142: 296-308.
18. Kim YS, Paik IY, Rhie YJ, Suh SH,. Integrative physiology: Defined novel metabolic roles of osteocalcin. J Korean Med Sci 2010; 25: 985-991.
19. Wei J, Ducy P,. Co-dependence of bone and energy metabolisms. Arch Biochem Biophys 2010; 503: 35-40.
20. Motyla KJ, McBea LR, Schwartz AV,. Bone and glucose metabolism: A two-way street. Arch Biochem Biophys 2010; 503: 2-10.
21. Mazali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J,. Osteopontin: A molecule for all seasons. Q J Med 2002; 95: 3-13.
22. Malaval L, Wade-Gueye NM, Boudiffa M, Fei J, Zirngibl R, Chen F, Laroche N, Roux JP, Burt-Pichat B, Duboef F, Boivin G, Jurdic P, Lafage-Proust MH, Amedee J, Vico L, Rossant J, Aubin JE,. Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis. J Exp Med 2008; 205: 1145-1153.
23. Dernhardt DT, Guo X,. Osteopontin: A protein with diverse functions. FASEB J 1993; 7: 1475-1482.
24. Alford AI, Hankenson KD,. Matricellular proteins: Extracellular modulators of bone development, remodeling, and regeneration. Bone 2006; 38: 749-757.
25. Seck T, Diel I, Bismar H, Ziegler R, Pfeilschiter J,. Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples. Eur J Endocrinol 2001; 145: 199-205.
26. Menezes R, Bramante CM, da Silva Paiva KB, Letra A, Carneiro E, Zambuzzi WF, Granjeiro JM,. Receptor activator NFkappaB-ligand and osteoprotegerin protein expression in human periapical cysts and granulomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 404-409.
27. Landry CS, Ruppe MD, Grubbs EG,. Vitamin D receptors and parathyroid glands. Endocr Pract 2011; 17: 63-68.
28. Jilka RL, O'Brien CA, Bartell SM, Weinstein RS, Manolagas SC,. Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms. J Bone Miner Res 2010; 25: 2427-2437.
29. Baron R, Rawadi G,. Minireview: Targeting the Wnt/B-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007; 148: 2635-2643.
30. Ma YA, Cain RL, Hallaway DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE,. Catabolic effects of continuous human PTH in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 2011; 142: 4047-4054.
31. Rude RK, Singer FR, Gruber HE,. Skeletal and hormonal effects of magnesium deficiency. J Am Coll Nutr 2009; 28: 131-141.
32. Kajhuria DK, Razdan R, Mahapatra DR,. Drugs for the management of osteoporosis: A review. Rev Bras Reumatol 2011; 51: 365-382.